SCHEMBL3145273

SCHEMBL3145273

COc1ccc(ON(c2ccccc2)S(=O)(=O)c2ccc(C(=O)NCCCN3CCCCC3)cc2)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
F10 P00742 1/20 0.46
POLB P06746 1/20 0.46
CCR2 P41597 3/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SMYD2 Q9NRG4 1/20 0.46
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
DRD2 P14416 4/20 0.45
DRD4 P21917 3/20 0.45
DRD3 P35462 3/20 0.45
TP53 P04637 1/20 0.45
KMT2A Q03164 1/20 0.44
HTR4 Q13639 1/20 0.44
MCHR2 Q969V1 1/20 0.44
MCHR1 Q99705 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3148189 0.95 POLB (0.52) F10POLBCCR2CA12CA9
SCHEMBL3148182 0.91 F10 (0.51) ALDH1A1SMN1; SMN2TDP1F10CCR2
SCHEMBL3140709 0.89 NAMPT (0.47) ALDH1A1SMN1; SMN2TDP1F10CCR2
SCHEMBL3153773 0.89 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2TDP1F10CCR2
SCHEMBL3149168 0.88 F10 (0.53) ALDH1A1SMN1; SMN2TDP1F10CCR2
SCHEMBL3149836 0.88 CCR2 (0.50) ALDH1A1SMN1; SMN2TDP1CCR2SMYD2
SCHEMBL3044072 0.86 F10 (0.46) ALDH1A1SMN1; SMN2TDP1F10CCR2
SCHEMBL3149321 0.84 KMT2A (0.47) ALDH1A1SMN1; SMN2DRD2DRD3KMT2A
SCHEMBL3139557 0.84 DRD4 (0.48) DRD2DRD4
SCHEMBL3153187 0.84 CA12 (0.50) ALDH1A1SMN1; SMN2CCR2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 ALDH1A1 3552/4885SMN1; SMN2 3719/4885TDP1 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.